K2 HealthVentures — 2021 Investments

1 investments dated 2021 · listed companies and verified rows first · show all

Umoja Biopharma, Inc.umoja-biopharma.comin 𝕏Jun 2021

Umoja Biopharma develops in vivo CAR T cell therapies for cancer treatment using its VivoVec platform, which generates CAR T cells directly in patients' bodies.

BiotechDigital HealthMedical DevicesSeattle, US

Philip S. Low(Director)Irena Melnikova(Executive Officer)Anna French(Director)Robert Glassman(Director)Andrew M. Scharenberg(Executive Officer, Director)

BoardJohn Hamer(Director)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.